Neurostimulation for Parkinson's disease with early motor complications.

By W. Schuepbach, J. Rau, K. Knudsen, J. Volkmann, P. Krack, L. Timmermann, T. Hälbig, Helke Hesekamp, S. Navarro, N. Meier and 40 more. New England Journal of Medicine, 2013

1,208 citations recorded by the source corpus.

Subfields: Neurology

View Paper: https://www.semanticscholar.org/paper/cb543cbd34b795ee1c16d3392bedbb80653fb74e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Neurology

Citations in the corpus

Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence‐based medicine review (2019, background): “” Regarding management of PDMCI or cognitive impairment short of dementia, the evidence is much more limited, for both PD and MCI in the general population with insufficient efficacy evidence for rasagiline and rivastigmine(7,33,36,134) and an unclear role of DBS surgery.(135,136) There is prelimina”
International Parkinson and movement disorder society evidence‐based medicine review: Update on treatments for the motor symptoms of Parkinson's disease (2018, background): “5 years) and was positive versus medical therapy.(140) A lower quality positive study evaluated STN and GPi DBS for gait and balance outcomes.”
Deep Brain Stimulation (2008, positive): “There have been additional published RCTs of deep brain stimulation for PD, which continue to report overall positive results [15-23].”
Connectivity Predicts Deep Brain Stimulation Outcome in Parkinson Disease (2017, background): “Deep brain stimulation (DBS) is a well-established treatment for Parkinson disease (PD), yielding improvements in motor symptoms and quality of life.(1) The most common DBS target is the subthalamic nucleus (STN), identified based on stereotactic coordinates and preoperative magnetic resonance imagi”